Medicinal chemistry

NRG Therapeutics Announces International Scientific Advisory Board

Retrieved on: 
Thursday, March 30, 2023
Society, Alzheimer's disease, Biogen, Genomics, Washington University in St. Louis, Science, Chemistry, MPTP, ALS, Northwestern University, SAB, University, Pharmacia, CSO, Research, DSM-IV codes, BOD, The Michael J. Fox Foundation, Drug discovery, Biology, Chronic pain, Michael, D, Medicinal chemistry, Neuropharmacology, Harvard University, Biotechnology, Howard Hughes, Government, Neuroscience Research Australia, AbbVie, Neurology, Therapy, Translation, NRG, Drug development, Milken Institute, Doctor of Philosophy, Kalpana, Eli Lilly, Mitochondrial permeability transition pore, Pharmaceutical industry, Medtronic

STEVENAGE, United Kingdom, March 30, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders.

Key Points: 
  • STEVENAGE, United Kingdom, March 30, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders.
  • NRG Therapeutics is applying breakthrough science in the field of mitochondrial biology to develop first-in-class treatments for Parkinson’s, ALS (also known as motor neurone disease) and other neurodegenerative disorders.
  • He currently serves on the board of directors and as an advisor to several biotechnology companies including Mission Therapeutics and Nitrase Therapeutics and is a venture partner with the Dementia Discovery Fund.
  • Since then, she has held executive (CEO, CSO) and advisory roles at early-stage companies as an SAB or BOD member.

BioDuro-Sundia Announces Formation of Scientific Advisory Board

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Molecule, SAB, Medicinal chemistry, University, ARCH Venture Partners, Denali, Berkeley, Stanford University, Harvard University, London Business School, Health care, Roche, IMD, Interline, Book, Spinal muscular atrophy, Novartis, Drug discovery, Advent International, Growth, Therapy, NIH, Pharmaceutical industry, Genentech, Chemistry

BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas Ph.D. and Zach Sweeney Ph.D. as its members.

Key Points: 
  • BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas Ph.D. and Zach Sweeney Ph.D. as its members.
  • “We welcome Andrew and Zach who bring valuable experience as we continue to accelerate our growth,” said Dr. Kent Payne, CEO of BioDuro-Sundia.
  • Zach was previously the Chief Scientific Officer at Denali Therapeutics and a leader in the drug discovery groups at Revolution Medicines, Novartis, Genentech, and Roche.
  • He is listed as an inventor on approximately 60 published patent applications and has co-authored more than 40 scientific publications.

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

Retrieved on: 
Friday, March 17, 2023
Medicinal chemistry, NBQX, University, AMPA, CNQX, Patient, Vanda, Master of Science, Novo Nordisk, IT University of Copenhagen, Pharmacy, Excitatory amino acid receptor agonist, Purdue Pharma, Copenhagen, Management, Neuropharmacology

WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc.

Key Points: 
  • WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc.
  • to its Board of Directors effective March 15, 2023.
  • Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent.
  • Dr. Honoré currently serves as President of Aestus Partners LLC, a business advisory firm with deep roots in the life sciences sector.

Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Retrieved on: 
Thursday, February 16, 2023
Chemical & Engineering News, Brain, Medicinal chemistry, Journal, Delix Therapeutics, Frontiers, Therapy, Serotonin, Psychedelic drug, Engineering News-Record, PTSD, European Journal of Medicinal Chemistry, Drug development, Patient, Depression, Schizophrenia, University, Olson, Behavior, Research, Cell, Posterior cortical atrophy, Knowledge, Deficit spending, Central nervous system, Selective serotonin reuptake inhibitor, Doctor of Philosophy, Pharmaceutical industry, Nature, Ramipril, Science, Psychiatry

BOSTON, Feb. 16, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying, neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, shared the findings of a new study published today in Science. The groundbreaking paper, authored by Delix Co-founder and Chief Innovation Officer David E. Olson, PhD, reveals the mechanism that causes serotonin and psychoplastogens to activate the 5-HT2A receptor in different ways.

Key Points: 
  • BOSTON, Feb. 16, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying, neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, shared the findings of a new study published today in Science.
  • The study uncovers the fact that intracellular 5-HT2A receptors mediate the psychoplastogenic effects of psychedelics.
  • As serotonin cannot activate this population of receptors, the study might explain why serotonin-based therapeutics - such as SSRIs, commonly prescribed antidepressants – have different effects than psychedelics and other psychoplastogenic therapeutics.
  • The Delix team continues to advance its unique scientific and talent advantage at the forefront of central nervous system drug development," added Mark Rus, CEO of Delix Therapeutics.

Halia Therapeutics Appoints Former Amgen Executive, Margit M. Janát-Amsbury, MD, Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, January 19, 2023
Neurodegeneration, Sumitomo Dainippon Pharma, SALT, University, Therapy, Division, NLRP3, Inflammation, Amgen, Biological engineering, Medicinal chemistry, Albertus Magnus College, University of Washington Department of Bioengineering, Gynecologic Oncology (journal), Nanomedicine, Pharmaceutical industry, MD

"I am honored to join Halia Therapeutics and work alongside this accomplished multi-disciplinary team of scientists and innovators.

Key Points: 
  • "I am honored to join Halia Therapeutics and work alongside this accomplished multi-disciplinary team of scientists and innovators.
  • The company's unique approach of targeting the NLRP3 inflammasome to resolve chronic inflammation has enormous potential within multiple therapeutic areas.
  • Prior to joining Halia Therapeutics as Chief Medical Officer, Dr. Janát-Amsbury served as an Executive Medical Director in Early Oncology Development at Amgen and was also the Product Team Lead for Amgen's prostate portfolio.
  • Before joining Amgen, she oversaw the development of multiple small molecules at Tolero Pharmaceuticals, which Sumitomo Dainippon Pharma acquired in 2017.

Scenic Biotech Strengthens Drug Discovery Expertise in Management Team with the Addition of Kristof Van Emelen

Retrieved on: 
Thursday, January 19, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Master of Science, Flanders Institute for Logistics, Johnson & Johnson, Gene, Medicinal chemistry, Therapy, Drug discovery, Patient, Patent, VIB, Kristof, Janssen Pharmaceuticals, Innovation, Doctor of Philosophy, Flanders, Pharmaceutical industry, KU Leuven

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced the appointment of Kristof Van Emelen, PhD, as Vice President of Drug Discovery.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced the appointment of Kristof Van Emelen, PhD, as Vice President of Drug Discovery.
  • At Scenic Biotech, Dr. Van Emelen will be responsible for the development of the company’s pipeline candidates based on genetic modifiers, genes that counteract the effect of a disease-causing gene.
  • I am looking forward to working with the Scenic Biotech team as we create novel treatment options for patients living with severe diseases,” commented Dr. Kristof Van Emelen, VP, Drug Discovery at Scenic Biotech.
  • Prior to Scenic Biotech, Dr. Van Emelen served as the Head of Medicinal Chemistry for Ermium Therapeutics, a French biotech developing therapeutics to treat auto-immune diseases.

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

Retrieved on: 
Wednesday, January 11, 2023
Master of Arts, Disease, New Drug Application, University, Virginia Tech, CNS, Regulation of tobacco by the U.S. Food and Drug Administration, Akrofi-Christaller Institute, NDAS, FDA, Senior, Drug development, State university system, NDA, Research and development, Medicinal chemistry, Central nervous system, Food, M.A, KMPH, Therapy, Glycogen storage disease, Neurodegeneration, Pain, Pharmaceutical industry, Research, ADHD, Biochemistry, Chemistry

CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer. Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm’s leadership team since the early days of the Company.

Key Points: 
  • Mickle, M.A., to Chief Product Development Officer.
  • Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm’s leadership team since the early days of the Company.
  • Dr. Guenther was one of the first members of KemPharm, most recently serving as the company’s Executive Vice President of Research and Development.
  • As Chief Scientific Officer, he will continue to lead KemPharm’s research team and play a central role in the advancement of the company’s pipeline.

Sai Life Sciences inks strategic agreement to set up Schrödinger's first dedicated offshore Research Laboratories in India

Retrieved on: 
Tuesday, January 10, 2023
Process chemistry, Drug discovery, Contract research organization, Research, Laboratory, ADME, Growth, Biology, Development, Discovery, Sai, Investment, Therapy, Medicinal chemistry, Analytical chemistry, Chemistry, FTE, SSRL, Fine chemical

HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Key Points: 
  • HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.
  • Being built inside Sai Life Sciences' R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry , in vitro biology , and process chemistry .
  • It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed.
  • Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "We're truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories.

Sai Life Sciences inks strategic agreement to set up Schrödinger's first dedicated offshore Research Laboratories in India

Retrieved on: 
Tuesday, January 10, 2023
Process chemistry, Drug discovery, Contract research organization, Research, Laboratory, ADME, Growth, Biology, Development, Discovery, Sai, Investment, Therapy, Medicinal chemistry, Analytical chemistry, Chemistry, FTE, SSRL, Fine chemical

HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Key Points: 
  • HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.
  • Being built inside Sai Life Sciences' R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry , in vitro biology , and process chemistry .
  • It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed.
  • Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "We're truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.